跳至主要内容
临床试验/JPRN-jRCTs041210044
JPRN-jRCTs041210044招募中2 期

Multicenter, open-label, uncontrolled study of azacitidine therapy for juvenile myelomonocytic leukemia - JPLSG-JMML-20

Muramatsu Hideki0 个研究点目标入组 30 人开始时间: 2021年7月26日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 < 10age old(—)
性别
All

入选标准

  • (1) Cases with a clinical diagnosis of JMML based on the JMML diagnostic criteria.
  • (2) Have submitted or are able to submit samples for central testing.
  • (3) Consent for CHM-14 was obtained prior to obtaining consent to participate in this study.
  • (4) Age at diagnosis is less than 10 years old.
  • (5) The patient has sufficient organ function to meet the following three criteria at the same time. Laboratory values within 7 days before the date of enrollment.
  • a) D-Bil level: less than 1.5 mg/dL
  • b) Creatinine: less than 3 times the upper limit of the age-specific test reference value
  • c) Left ventricular ejection fraction (EF) >=50% by echocardiography
  • (6) Adequate explanations and written consent have been obtained from the proxy.

排除标准

  • (1) Noonan syndrome (a case of PTPN11 germ cell mutation)
  • (2) Associated with difficult-to-control infections (including active tuberculosis and HIV antibody-positive cases).
  • (3) Relapse cases with a history of hematopoietic cell transplantation.
  • (4) Any other case deemed inappropriate by the doctor in charge.

研究者

发起方
Muramatsu Hideki

相似试验